AKT1 and glioblastoma: A phase I/II clinical trial in recurrent HGGs (NCT01051557) was characterized by a combination of the Akt inhibitor Perifosine and Temsirolimus, which together inhibited murine GBM growth regardless of the PTEN status [178,179].